Nevirapine or efavirenz in combination with two nucleoside analogues in HIV-infected antiretroviral-naive patients;Nevirapina o efavirenz en combinación con dos análogos de nucleósidos en pacientes con infección por el VIH sin tratamiento previo

Medicina Interna de Mexico

Volumn 20, Issue 1, 2004, Pages 24-33

  Gaytán, Juan Jacobo Ayala ^a   De La Garza, Eduardo Roger Zapata ^a   García, Marcelino Chávez ^a   Chávez, Salvador Bruno Valdovinos ^a  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

Author keywords

Efavirenz; HIV infection; Nevirapine

Indexed keywords

EFAVIRENZ; LAMIVUDINE PLUS ZIDOVUDINE; NEVIRAPINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; OUTPATIENT CARE; RANDOMIZED CONTROLLED TRIAL; UNSPECIFIED SIDE EFFECT; VIRUS LOAD;

EID: 35348891998     PISSN: 01864866     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. DHHS panel on clinical practices for treatment of HIV infection. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Feb 4, 2002.
2. Yeni PG, Hammer SM, Carpenter CC, Cooper DA, Fischl MA, Gatell JM, et al. Antiretroviral treatment for adult HIV infection in 2002. Update recommendations of the International AIDS Society-USA Panel. JAMA 2002;288:222-35.
3. AMMVIH. Guía para el uso de medicamentos antirretrovirales en pacientes con VIH/SIDA 2002. Asociación Médica Mexicana de VIH/SIDA, A.C. México, 2002.
4. Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1992;41:1-19.
5. Staszewski S, Morales-Ramírez J, Tashima K, Rachlis A, Skiest D, Stanford J, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV infection in adults. N Engl J Med 1999;341:1865-73.
6. th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, 1999 (Abstract LB22).
7. th Conference on Retrovirus and Oportunistic Infections. San Francisco, CA, 2000 (Abstract 510).
8. Torre D, Tambini R, Speranza F. Nevirapine or efavirenz combined with two nucleoside reverse transcriptase inhibitors compared to HAART: A meta-analysis of randomized clinical trials. HIV Clin Trials 2002;2:113-21.
9. Matthews GV, Sabin CA, Mandalia S, Lampe F, Phillips AN, Nelson MR, et al. Virological supression at 6 months is related to choice of initial regimen in antiretroviral-naive patients: a cohort study. AIDS 2002;16:53-61.
10. Cozzi-Lepri A, Phillips AN, Monforte AA, Piersantelli N, Orani A, Petrosillo N, et al. Virological and immunologic response to regimens containing nevirapine or efavirenz in combination with 2 nucleoside analogues in the Italian Cohort Naive Antiretrovirals (I.Co.N.A.) study. J Infect Dis 2002;185:1062-69.
11. Nuñez M, Soriano V, Martin-Carbonero L, Barrios A, et al. SENC (Spanish efavirenz vs. nevirapine comparison) trial: a randomized, open-label study in HIV-infected naive individuals. HIV Clin Trials 2002;3:186-94.
12. Keiser P, Nassar N, White C, Koen G, Moreno S. Comparison of nevirapine and efavirenz containing antiretroviral regimens in antiretroviral naive patients: a cohort study. HIV Clin Trials 2002;3:296-303.
13. 3. XIV International AIDS Conference. Barcelona, 2002 (Abstract 4457).
14. Hartmann M, Rump A, Brust J, Schuster D, Mosthaf F, Procacchianti M, et al. Comparison of efavirenz and nevirapine in antiretroviral naive and pretreated patients in a real world setting. XIV International AIDS Conference, Barcelona, 2002 (Abstract 4471).